GlobeNewswire

Trifacta Raises $48 Million in Financing to Democratize Data Wrangling

Dela

Demand for Trifacta's Market-Leading Platform Accelerates as Customer Base Triples in 2017

 

SAN FRANCISCO, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Trifacta, the global leader in data wrangling, announced $48 million in financing from new strategic investors, including Columbia Pacific, Deutsche Börse, Ericsson, Google, and New York Life along with participation from existing investors Accel, Cathay Innovation, Greylock Partners, Ignition Partners, and Ridge Ventures. This brings Trifacta's total financing to $124 million to date.

Building on the company's more than 3x increase in customer count, the new funding will support continued development of Trifacta's award-winning data wrangling platform and accelerate the company's continued cloud and geographic expansion. According to IDC, the big data and business analytics market will be worth $210 billion by 2020, and the market for data wrangling technologies is anticipated to grow 2.5x faster than the market for traditional data preparation tools. In addition, Gartner reports 1 that data preparation technologies will be used in more than 50 percent of new data integration efforts for analytics by 2020.

"Investing in and partnering with Trifacta, an innovator with its leading data wrangling offering, helps us expand our capabilities in data-driven areas such as risk management, investment decision making and trading analytics meaningfully," said Ankur Kamalia, MD & Head of Venture Portfolio Management and DB1 Ventures, Deutsche Börse.

"Trifacta's cutting-edge technology, client success and vision position the company for continued growth," said Paul McNamara, VP of Ericsson Ventures. "Ericsson is honored to invest with Trifacta to help drive further momentum in data wrangling that will help our telecommunications customers to get actionable insights and create business value from their data."

"At New York Life, we're keenly focused on new analytics technologies to enhance our speed to insight," said Joel Albarella, Head of New York Life Ventures. "As part of this effort, we're investing in Trifacta for its forward-thinking approach to data wrangling."

Accelerating Corporate Momentum in 2017

Trifacta continues to engage customers deeply around their most important business initiatives, dramatically shrinking the most tedious, expensive, and time-consuming part of the analytics process. Trifacta automates the discovery of new insights by helping users who know the data best stitch together complex data across transactions, interactions and behavior.

"Commerzbank is a leading international commercial bank and the second largest bank in Germany. As we embarked on creating a Big Data & Advanced Analytics division within Commerzbank, we knew that data wrangling technology would be a critical investment for its success; Trifacta was absolutely the right choice," said Kerem Tomak, EVP & Divisional Board Member, Big Data & Advanced Analytics at Commerzbank. "Easy to use and integrate across a broad range of employees, Trifacta is a core part of our efforts to accelerate our analytics projects. As a result this will help us expand our existing efforts around data quality, fast response to ad-hoc requests, big data analytics monetization for retail and corporate clients, and risk and compliance reporting."

Using the Trifacta platform, customers are able to balance the need for self-service and the need for data governance through collaborative curation and crowdsourcing of new data products. This makes the data understandable and useful for analysis regardless of where it lives or how it is consumed. Trifacta makes wrangling data fun, using an entirely new approach - attacking the problem through user experience and machine learning. 

"Data is bigger, it's messier and it's changing faster than ever before. Solving for this requires customers to modernize their analytic stack to achieve better economics and improved agility. It has become essential to democratize the production of new data assets with self-service data wrangling in much the same way enterprises previously democratized the consumption of data with self-service BI," said Adam Wilson, CEO at Trifacta. "At precisely this moment, Trifacta offers a mature platform built for big data, cloud, and self-service. We also offer the credibility of being the pioneer and the established leader in the data wrangling market."

Additional company milestones from 2017 include:

  • Drove significant customer adoption among industry leaders such as GlaxoSmithKline, Bank of America, Royal Bank of Scotland, Commerzbank, PepsiCo, eBay, Enstar, Deutsche Börse, Centers for Disease Control (CDC), New York Life, BNSF Railway Company, and Nordea Bank. 
     
  • Introduced significant product advancements to  Wrangler Enterprise: Ensuring the success of broader enterprise deployments, Trifacta improved the platform's user experience and performance, and built functionality to support "groups and loops." Enhanced collaboration enables groups of Trifacta users to share work with their colleagues and build collective knowledge across teams; adding data wrangling flows, self-service scheduling and broader connectivity allows users to more effectively build loops out of their work through repeated use. End users are able to not only build their own wrangling workflows in Trifacta, but also automate pipelines and manage versions. 
     
  • Established leadership in cloud data wrangling: Trifacta delivered on the vision to make its data wrangling solution work seamlessly across hybrid and multi-cloud environments. Trifacta supports deployments in popular cloud ecosystems Amazon Web Services (AWS), Google Cloud Platform (GCP) and Microsoft Azure. The past six months have seen record growth for Trifacta's cloud offerings, which have been adopted by more than 10,000 users across over 200 accounts. Trifacta also launched Cloud Data Prep on GCP in conjunction with Google, and is now listed in the AWS Marketplace and featured as part of the AWS machine learning competency. 

  • Recognized as the No. 1 data preparation solution in every independent and analyst ranking: According to a Q1 2017 Forrester Wave report - Forrester's widely respected evaluation of vendors in a given market - "Trifacta delivers a strong balance for self-service and business users."2 Dresner Advisory Services' End User Data Preparation Survey ranked Trifacta the No. 1 data preparation vendor of 2017, the third year in a row. In the Gartner Research Market Guide for Data Preparation, Trifacta demonstrated support in all of the established capabilities for "Data Transformation, Blending and Modeling," "Diverse Data Sources," and "Data Exploration." 
     
  • Added world's largest consulting and technology providers to partner ecosystem: In 2017, Trifacta greatly expanded the company's technology, systems integrator and consulting partner ecosystem. Trifacta announced integration and joint customer success with a number of leading data cataloging vendors including Alation as well as a number of leading data science platforms such as DataRobot. Trifacta is also now embedded as the data wrangling standard within the Infosys Information Platform (IIP), Leidos Collaborative Analytics and Data Sharing Platform (CAADS), and Wipro Data Discovery Platform (WDDP). In addition to this, FICO now offers Trifacta as a high-end wrangling option as part of the FICO Decision Management Suite. 

  • Expanded executive team: Trifacta continues to strengthen its executive team with the addition of proven industry leaders. Zarnaz Arlia has joined as vice president of marketing. Zarnaz was formerly with Neustar as the head of corporate marketing, responsible for the company's brand and marketing strategy as well as go-to-market initiatives. Prior to Neustar, Zarnaz held executive marketing roles at Qualys and Adobe. Bryan Plaster has joined as the vice president of customer success and services. Bryan was formerly the head of customer success for Talend and, prior to that, ran customer success for Informatica's cloud business. Yuri Bukhan has joined as the vice president of alliances. Yuri was formerly head of ISV alliances for Cloudera in addition to his broad experience in data and analytics at GoodData, Pentaho, and Tibco.

To experience Trifacta firsthand, download the newest Trifacta Wrangler for free today at https://www.trifacta.com/start-wrangling/

About Trifacta:
Trifacta is the global leader in data wrangling. Trifacta leverages decades of innovative research in human-computer interaction, scalable data management and machine learning to make the process of preparing data faster and more intuitive. Around the globe, tens of thousands of users at more than 10,000 companies, including leading brands like Deutsche Börse, Kaiser Permanente, New York Life and PepsiCo, are unlocking the potential of their data with Trifacta's market-leading data wrangling solutions. Learn more at trifacta.com.

Gartner Disclaimer: 
*Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

1Gartner, Market Guide for Data Preparation, Ehtisham Zaidi, Rita L. Sallam, Shubhangi Vashisth, 14 December 2017

2 Forrester Research, Inc., The Forrester Wave(TM): Data Preparation Tools, Q1 2017, by Cinny Little, Gene Leganza, Jun Lee; March 13, 2017

Media Contacts:
Jennifer Harlan
trifacta@highwirepr.com (415) 963-4174




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Trifacta via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in October and November22.10.2018 16:00Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Announces Upcoming Investor Events in October and November Immunicum AB (publ; IMMU.ST) announced today that the Company will participate in and host investor events in October and November. At all events Carlos de Sousa, CEO of Immunicum, and other members of the management team, will provide a corporate presentation and be available for a question and answer session. BioStock Life Science Summit Date: October 25, 2018 Presentation Time: 18.50 Central European Time Venue: Medicon Village, Scheelevägen 2, Building 302-auditorium, Lund, Sweden Registration Link: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicum Investor Event - Gothenburg Date: October 29, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venue: First Hotel G, Nils Ericsonplatsen, 411 03 Gothenburg, Sweden Immunicum Investor Event - Stockholm Date: October 30, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venu

Immunicum AB (publ) meddelar kommande investerarevent under oktober och november22.10.2018 16:00Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) meddelar kommande investerarevent under oktober och november Immunicum AB (publ; IMMU.ST) meddelar i dag att bolaget kommer att anordna och delta i investerarträffar under oktober och november. Vid samtliga event kommer Carlos de Sousa, Immunicums VD, och övriga medlemmar av ledningsgruppen, att hålla en presentation av bolaget och vara tillgängliga för att svara på frågor. BioStock Life Science Summit Datum: 25 oktober 2018 Presentationstid: Kl. 18.50 CET Plats: Medicon Village, Scheelevägen 2, byggnad 302 - hörsalen, Lund Länk för registrering: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicums investerarevent - Göteborg Datum: 29 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: First Hotel G, Nils Ericsonplatsen, 411 03, Göteborg Immunicums investerarevent - Stockholm Datum: 30 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: Ingenjörshuset Citykonferensen, Plan 1, Malmski

Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum